| abstract |
Disclosed is a use of a multi-target tyrosine kinase inhibitor in combination with an EGFR inhibitor in preparing a drug for treating a tumor. In particular, the multi-target tyrosine kinase inhibitor described in the present application is selected from a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and the EGFR inhibitor is selected from a compound represented by formula (II) or a stereoisomer, complex, or pharmaceutically acceptable salt thereof. (I), (II) |